» Authors » M S Hudecki

M S Hudecki

Explore the profile of M S Hudecki including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 33
Citations 190
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Hartel J, Granchelli J, Hudecki M, Pollina C, Gosselin L
Muscle Nerve . 2001 May; 24(3):428-32. PMID: 11353432
The purpose of this study was to assess the impact of prednisone treatment for 8 weeks on the level of transforming growth factor-beta 1 (TGF-beta1), hydroxyproline (HYP) concentrations, and level...
2.
Granchelli J, Pollina C, Hudecki M
Neuromuscul Disord . 2000 Jun; 10(4-5):235-9. PMID: 10838248
The genetically dystrophin-deficient mdx mouse, with its characteristic and regular exercise-induced loss of strength, is a useful experimental platform on which to screen potential drug therapies in the treatment of...
3.
Granchelli J, Avosso D, Hudecki M, Pollina C
Res Commun Mol Pathol Pharmacol . 1996 Mar; 91(3):287-96. PMID: 8829768
Exercised mdx mice were used to evaluate the efficacy of two pharmacologic entities, cromolyn and compound 48/80. Beginning at 2 weeks of age, mdx mice were treated with either cromolyn...
4.
Granchelli J, Pollina C, Hudecki M
J Neurol Sci . 1995 Jul; 131(1):1-7. PMID: 7561939
Dystrophin-deficient female mdx mice were bred with male Tsk+/+ pa mice to examine the role played by mast cells in the pathophysiology of dystrophin deficiency. Resultant mdx/Tsk double-mutant mice were...
5.
Hudecki M, Povoski S, Gregorio C, Granchelli J, Pollina C
J Appl Physiol (1985) . 1995 Jun; 78(6):2014-9. PMID: 7665393
Autosomal-recessive dystrophic chickens were treated in three experimental groups with an intraperitoneal multicomponent drug mixture (50 mg/kg Ep475, 20 mg/kg Cinanserin, 10 mg/kg stanazolol, 100 mg/kg leucine, 0.1 mg/kg insulin,...
6.
Granchelli J, Hudecki M, Pollina C
Res Commun Chem Pathol Pharmacol . 1994 Jun; 84(3):351-62. PMID: 7938907
Species-specific differences in the inflammatory response, specifically with regard to mast cells, have been proposed to explain the phenotypic variation among dystrophin-deficient humans, and mdx mice (Gorospe et al., 1994)....
7.
Hudecki M, Pollina C, Granchelli J, Daly M, Byrnes T, Wang J, et al.
Res Commun Chem Pathol Pharmacol . 1993 Jan; 79(1):45-60. PMID: 8434132
The dystrophin-deficient, X-linked dystrophic mouse (mdx) was used to evaluate the efficacy of prednisolone treatment. A test protocol was used to take advantage of the quantifiable weakness and disability as...
8.
Hudecki M, Pollina C
Adv Exp Med Biol . 1990 Jan; 280:251-63; discussion 263-5. PMID: 2248146
No abstract available.
9.
Brazeau G, Hudecki M, Fung H
Res Commun Chem Pathol Pharmacol . 1989 Mar; 63(3):439-50. PMID: 2727393
The dystrophic chicken line 413 (University of California, Davis) and its genetically related normal line 412 were investigated for possible differences in serum blood chemistry indices and hepatic cytochrome P-450...
10.
Galindo Jr J, Hudecki M, DAVIS F, Davis P, Thacore H, Pollina C, et al.
Biochemistry . 1988 Sep; 27(19):7519-24. PMID: 2974724
A skeletal muscle membrane fraction enriched in sarcoplasmic reticulum (SR) contained Ca2+-ATPase activity which was stimulated in vitro in normal chickens (line 412) by 6 nM purified bovine calmodulin (33%...